“`html
Published: 2025/10/04 08:45:49
Metabolic Associated Steatohepatitis (MASH) Linked to Increased mortality Risk
Table of Contents
A recent study published in teh journal HEALIO Gastroenterology has revealed a notable association between Metabolic Associated Steatohepatitis (MASH), formerly known as Metabolic Associated Steatotic Liver Disease (MASLD), and an increased risk of all-cause mortality. The research, analyzing data from a large cohort of U.S. adults,highlights the importance of addressing cardiometabolic risk factors in individuals with MASH.
Understanding MASH (Formerly MASLD)
MASH is a severe form of nonalcoholic fatty liver disease (NAFLD). It’s characterized by inflammation and liver damage caused by a buildup of fat in the liver, and is strongly linked to metabolic conditions like obesity, type 2 diabetes, and high blood pressure. The name change from MASLD to MASH in 2023 reflects a better understanding of the disease’s underlying pathology, emphasizing the role of metabolic dysfunction and inflammation.
Key Findings of the study
Researchers analyzed data from 134,515 participants aged 20 years or older in the United States, spanning the years 1988 to 2018. The study identified approximately 21,000 individuals who qualified as having MASH. The study focused on tracking all-cause mortality rates in relation to individual cardiometabolic risk factors.
The study found that the risk of mortality increased significantly with the number of cardiometabolic risk factors present in individuals with MASH. Specifically, those with multiple risk factors – such as diabetes, hypertension, and dyslipidemia (abnormal lipid levels) – experienced a substantially higher risk of death compared to those with fewer risk factors. The researchers emphasized that addressing these co-existing conditions is crucial for improving outcomes for patients with MASH.
Cardiometabolic Risk Factors and MASH
Cardiometabolic risk factors are a cluster of conditions that increase the risk of both cardiovascular disease and metabolic disorders like diabetes.Common factors include:
- Obesity: excess body weight,particularly around the abdomen.
- Type 2 Diabetes: A condition where the body doesn’t use insulin properly, leading to high blood sugar.
- Hypertension (High Blood Pressure): Force of blood against artery walls is consistently too high.
- Dyslipidemia: Abnormal levels of cholesterol and other fats in the blood.
- Insulin Resistance: Cells don’t respond effectively to insulin.
Future Research Directions
The study authors plan to conduct further research to investigate the role of genetic factors, dietary habits, and alcohol consumption in MASH outcomes. “The more we can understand about the drivers of the disease, the more we can identify those most in need of interventions and prioritize our resources for enhanced outcomes,” stated Dr. Terrault, a study author. This future research aims to develop more complete risk profiles and personalized treatment strategies.
Liyun Yuan, MD, a transplant hepatologist with Keck Medicine, also contributed to the study.
Key Takeaways
- MASH (formerly MASLD) is associated with an increased risk of all-cause mortality.
- the risk of mortality